A novel inflammation-related lncRNAs prognostic signature identifies LINC00346 in promoting proliferation, migration, and immune infiltration of glioma

In this study, a total of 13 inflammation-related lncRNAs with a high prognostic value were identified with univariate, multivariate Cox regression analysis, and LASSO analysis. LINC00346, which is one of the 13 lncRNAs identified, was positively associated with type 2 macrophage activation and the...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 810572
Main Authors Zeng, Wen-Jing, Zhang, Lei, Cao, Hui, Li, Dongjie, Zhang, Hao, Xia, Zhiwei, Peng, Renjun
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 13.10.2022
Subjects
glioma
Immunology
inflammation
lncRNA
prognostic
target
Online AccessGet full text

Cover

More Information
Summary:In this study, a total of 13 inflammation-related lncRNAs with a high prognostic value were identified with univariate, multivariate Cox regression analysis, and LASSO analysis. LINC00346, which is one of the 13 lncRNAs identified, was positively associated with type 2 macrophage activation and the malignant degree of glioma. Fluorescence in situ hybridization (FISH) and immunohistochemical staining showed that LINC00346 was highly expressed in high-grade glioma, while type 2 macrophages key transcription factor STAT3 and surface marker CD204 were also highly expressed simultaneously. LINC00346 high-expression gliomas were more sensitive to the anti–PD-1 and anti-CTLA-4 therapy. LINC00346 was also associated with tumor proliferation and tumor migration validated by EdU, cell colony, formation CCK8, and transwell assays. These findings reveal novel biomarkers for predicting glioma prognosis and outline relationships between lncRNAs inflammation, and glioma, as well as possible immune checkpoint targets for glioma.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Tao Xin, Qianfoshan Hospital, Shandong University, China; Guangzhi Zhang, Lanzhou University, China; Yingkun Xu, Chongqing Medical University, China
Edited by: Linlang Guo, Zhujiang Hospital, China
These authors have contributed equally to this work
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.810572